highlights

accesso Highlights Industry-Leading Guest Experience Solutions at IAAPA Expo Orlando 2024

ORLANDO, Fla., Nov. 15, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment…

1 month ago

accesso Highlights Industry-Leading Guest Experience Solutions at IAAPA Expo Orlando 2024

ORLANDO, Fla., Nov. 15, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment…

1 month ago

accesso Highlights Industry-Leading Guest Experience Solutions at IAAPA Expo Orlando 2024

ORLANDO, Fla., Nov. 15, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment…

1 month ago

accesso Highlights Industry-Leading Guest Experience Solutions at IAAPA Expo Orlando 2024

ORLANDO, Fla., Nov. 15, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment…

1 month ago

accesso Highlights Industry-Leading Guest Experience Solutions at IAAPA Expo Orlando 2024

ORLANDO, Fla., Nov. 15, 2024 /PRNewswire/ -- accesso Technology Group (AIM: ACSO), the premier technology solutions provider for attractions, leisure, entertainment…

1 month ago

New Generative AI Study Highlights Adoption, Use and Opportunities in the Legal Industry

69% of legal professionals report their generative AI use will continue to increase in the next two years CHICAGO, Nov.…

1 month ago

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its…

1 month ago

New Generative AI Study Highlights Adoption, Use and Opportunities in the Legal Industry

69% of legal professionals report their generative AI use will continue to increase in the next two years CHICAGO, Nov.…

1 month ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort…

1 month ago